{"classes":[{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"-4.5"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"0.00","value":"-7.1"},{"groupId":"OG003","spread":"0.00","value":"-3.6"},{"groupId":"OG004","spread":"0.00","value":"-10.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.72","value":"1.6"},{"groupId":"OG001","spread":"10.61","value":"0.9"},{"groupId":"OG002","spread":"10.60","value":"1.8"},{"groupId":"OG003","spread":"12.82","value":"0.8"},{"groupId":"OG004","spread":"11.82","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"74"},{"groupId":"OG004","value":"72"}],"units":"Participants"}],"title":"Week 72"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"88"},{"groupId":"OG002","value":"88"},{"groupId":"OG003","value":"88"},{"groupId":"OG004","value":"88"}],"units":"Participants"}],"description":"Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.","dispersionType":"Standard Deviation","groups":[{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG000","title":"Pasireotide LAR Overall - AcroQOL Total Scores"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG001","title":"Pasireotide LAR Overall - AcroQOL Physical Sub-scores"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG002","title":"Pasireotide LAR Overall - AcroQOL Psychological Sub-scores"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG003","title":"Pasireotide LAR Overall - AcroQOL Psycho/Appearance Sub-scores"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG004","title":"Pasireotide LAR Overall-AcroQOL Psycho/Pers Relatns Sub-scores"}],"paramType":"MEAN","populationDescription":"Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 48, 60 & 72","title":"Extension Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}